Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution-Reference-Cited by-同舟云学术

Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution

Published:2024-05-09 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Gavira Javier^ORCID,Tapia Jose Carlos,Romano Alejandra^ORCID,Anguera Georgia^ORCID,Aguado María,Piedra Aida,Bosma Freya,Sánchez Sofía,Martin Cristina,Algaba Ferran,Arce Yolanda,Ramón y Cajal Teresa,Maroto Pablo^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03483-8.pdf

Reference11 articles.

1. Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albigès L, et al. PARP inhibition, a new therapeutic avenue in patients with prostate cancer. Drugs. 2022;82(7):719–33. https://doi.org/10.1007/s40265-022-01703-5.

2. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–102. https://doi.org/10.1056/NEJMoa1911440.

3. Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, TRITON3 Investigators, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719–32. https://doi.org/10.1056/NEJMoa2214676.

4. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750–68. https://doi.org/10.1016/j.annonc.2022.05.520.

5. Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490–503. https://doi.org/10.1200/JCO.18.00358.